Table 1.
Study | Location | Convalescent plasma |
Control |
Statistics |
||||||
---|---|---|---|---|---|---|---|---|---|---|
Survivor | Nonsurvivor | Mortality (%) | Survivor | Nonsurvivor | Mortality (%) | OR | P | 95% CI | ||
Randomized clinical trials | ||||||||||
Avendano-Sola et al18 | Spain | 38 | 0 | 0 | 39 | 4 | 9 | 0.11 | .15 | 0.01-2.19 |
Rasheed et al17 | Iraq | 20 | 1 | 5 | 20 | 8 | 29 | 0.13 | .06 | 0.01-1.09 |
Gharbharan et al13 | The Netherlands | 37 | 6 | 14 | 32 | 11 | 26 | 0.47 | .18 | 0.16-1.42 |
AlQahtani et al26 | Bahrain | 19 | 1 | 5 | 18 | 2 | 10 | 0.47 | .56 | 0.04-5.69 |
Libster et al27 | Argentina | 78 | 2 | 3 | 76 | 4 | 5 | 0.49 | .41 | 0.09-2.74 |
Li et al12 | China | 43 | 8 | 16 | 38 | 12 | 24 | 0.59 | .30 | 0.22-1.59 |
Ray et al28 | India | 30 | 10 | 25 | 26 | 14 | 35 | 0.62 | .33 | 0.24-1.63 |
Simonovich et al29 | Argentina | 197 | 25 | 11 | 93 | 12 | 11 | 0.98 | .96 | 0.47-2.04 |
Agarwal et al30 | India | 201 | 34 | 14 | 198 | 31 | 14 | 1.08 | .77 | 0.64-1.83 |
Bajpai et al31 | India | 11 | 3 | 21 | 14 | 1 | 7 | 3.82 | .27 | 0.35-41.96 |
Random effects model | 674 | 90 | 12 | 554 | 99 | 15 | 0.76 | .14 | 0.54-1.09 | |
Random effects model excluding Agarwal et al | 473 | 56 | 11 | 356 | 68 | 16 | 0.65 | .04 | 0.43-0.98 | |
Matched control studies | ||||||||||
Duan et al32 | China | 10 | 0 | 0 | 7 | 3 | 30 | 0.10 | .15 | 0.01-2.28 |
Perotti et al42 | Italy | 43 | 3 | 7 | 16 | 7 | 30 | 0.16 | .01 | 0.04-0.69 |
Omrani et al44 | Qatar | 39 | 1 | 3 | 35 | 5 | 13 | 0.18 | .13 | 0.02-1.61 |
Hegerova et al45 | Washington | 18 | 2 | 10 | 14 | 6 | 30 | 0.26 | .13 | 0.05-1.49 |
Salazar et al,33 | Texas | 146 | 6 | 4 | 235 | 34 | 13 | 0.28 | .01 | 0.12-0.69 |
Alsharidah et al46 | Kuwait | 111 | 24 | 18 | 143 | 90 | 39 | 0.34 | <.001 | 0.21-0.57 |
Zeng et al47 | China | 1 | 5 | 83 | 1 | 14 | 93 | 0.36 | .50 | 0.02-6.85 |
Donato et al48 | New York | 36 | 11 | 23 | 775 | 565 | 42 | 0.42 | .01 | 0.21-0.83 |
Salazar et al49 | Argentina | 647 | 221 | 25 | 1288 | 1010 | 44 | 0.44 | <.001 | 0.37-0.52 |
Liu et al50 | New York | 34 | 5 | 13 | 118 | 38 | 24 | 0.46 | .13 | 0.17-1.25 |
Xia et al34 | China | 135 | 3 | 2 | 1371 | 59 | 4 | 0.52 | .27 | 0.16-1.67 |
Abolghasemi et al16 | Iran | 98 | 17 | 15 | 56 | 18 | 24 | 0.54 | .10 | 0.26-1.13 |
AlShehry et al35 | Saudi Arabia | 30 | 10 | 25 | 78 | 46 | 37 | 0.57 | .16 | 0.25-1.26 |
Budhiraja et al36 | India | 248 | 85 | 26 | 241 | 120 | 33 | 0.69 | .03 | 0.50-0.96 |
ah Yoon et al37 | New York | 50 | 23 | 32 | 45 | 28 | 38 | 0.74 | .39 | 0.37-1.46 |
Rogers et al38 | Rhode Island | 56 | 8 | 13 | 149 | 28 | 16 | 0.76 | .52 | 0.33-1.77 |
Altuntas et al39 | Turkey | 669 | 219 | 25 | 642 | 246 | 28 | 0.85 | .15 | 0.69-1.06 |
Klapholz et al40 | New Jersey | 37 | 10 | 21 | 38 | 9 | 19 | 1.14 | .80 | 0.42-3.13 |
Klein et al41 | Maryland | 25 | 9 | 26 | 26 | 8 | 24 | 1.17 | .78 | 0.39-3.51 |
Moniuszko-Malinowska et al43 | Poland | 49 | 6 | 11 | 672 | 43 | 6 | 1.91 | .16 | 0.78-4.72 |
Random effects model | 2482 | 668 | 21 | 5950 | 2377 | 29 | 0.57 | <.001 | 0.45-0.72 | |
Overall random effects modelb | 2955 | 724 | 20 | 6306 | 2445 | 28 | 0.58 | <.001 | 0.47-0.71 |
OR, odds ratio.
Random effects model excludes trial by Agarwal et al.